MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-20T20:54:00Z
Salesforce, Blue Shield CA will partner to create an all-AI healthcare approval system
Mon 21 Oct 24, 12:00 PMSlowing Rates Of Return At UnitedHealth Group (NYSE:UNH) Leave Little Room For Excitement
Sat 19 Oct 24, 11:00 AMZacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare
Fri 18 Oct 24, 01:14 PMPharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO
Fri 18 Oct 24, 11:14 AMElevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations
Thu 17 Oct 24, 05:29 PMBrokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet
Wed 16 Oct 24, 01:30 PMUnitedHealth Group Inc (UNH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Wed 16 Oct 24, 07:01 AMQ3 2024 Unitedhealth Group Inc Earnings Call
Wed 16 Oct 24, 03:16 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 26343.00M | 22310.00M | 20742.00M | 17981.00M | 15944.00M |
| Minority interest | -519.00000M | -447.00000M | 366.00M | 400.00M | 396.00M |
| Net income | 20120.00M | 17285.00M | 15403.00M | 13839.00M | 11986.00M |
| Selling general administrative | 47782.00M | 42579.00M | 41704.00M | 35193.00M | 34074.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 77587.00M | 67328.00M | 65498.00M | 55712.00M | 52470.00M |
| Reconciled depreciation | 3400.00M | 3103.00M | 2891.00M | 2720.00M | 2428.00M |
| Ebit | 28435.00M | 23970.00M | 22405.00M | 19685.00M | 15968.00M |
| Ebitda | 29805.00M | 24749.00M | 23794.00M | 20519.00M | 18396.00M |
| Depreciation and amortization | 1370.00M | 779.00M | 1389.00M | 834.00M | 2428.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 28435.00M | 23970.00M | 22405.00M | 19685.00M | 17344.00M |
| Other operating expenses | 295727.00M | 263627.00M | 234736.00M | 222470.00M | 208903.00M |
| Interest expense | 2092.00M | 1660.00M | 1663.00M | 1704.00M | 1400.00M |
| Tax provision | 5704.00M | 4578.00M | 4973.00M | 3742.00M | 3562.00M |
| Interest income | 2092.00M | 1660.00M | 1663.00M | 1704.00M | 1400.00M |
| Net interest income | -2092.00000M | -1660.00000M | -1663.00000M | -1704.00000M | -1400.00000M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 5704.00M | 4578.00M | 4973.00M | 3742.00M | 3562.00M |
| Total revenue | 322132.00M | 285273.00M | 255639.00M | 240269.00M | 224871.00M |
| Total operating expenses | 51182.00M | 45682.00M | 44595.00M | 37913.00M | 36502.00M |
| Cost of revenue | 244545.00M | 217945.00M | 190141.00M | 184557.00M | 172401.00M |
| Total other income expense net | -2092.00000M | -1660.00000M | -1663.00000M | -1704.00000M | 1376.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 20639.00M | 17732.00M | 15769.00M | 14239.00M | 12382.00M |
| Net income applicable to common shares | 20120.00M | 17285.00M | 15403.00M | 13839.00M | 11986.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 245705.00M | 212206.00M | 197289.00M | 173889.00M | 152221.00M |
| Intangible assets | 14401.00M | 10044.00M | 10856.00M | 10349.00M | 9325.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 23477.00M | 23635.00M | 21067.00M | 16567.00M | 12980.00M |
| Total liab | 159358.00M | 135727.00M | 126750.00M | 111727.00M | 95994.00M |
| Total stockholder equity | 81450.00M | 75045.00M | 68328.00M | 60436.00M | 54319.00M |
| Deferred long term liab | 2769.00M | 3265.00M | 3367.00M | 2993.00M | 2474.00M |
| Other current liab | 53996.00M | 47618.00M | 42887.00M | 33600.00M | 28949.00M |
| Common stock | 9.00M | 10.00M | 10.00M | 9.00M | 10.00M |
| Capital stock | 9.00M | 10.00M | 10.00M | 9.00M | 10.00M |
| Retained earnings | 86156.00M | 77134.00M | 69295.00M | 61178.00M | 55846.00M |
| Other liab | 11775.00M | 15052.00M | 15682.00M | 9982.00M | 8204.00M |
| Good will | 93352.00M | 75795.00M | 71337.00M | 65659.00M | 58910.00M |
| Other assets | 20714.00M | 107334.00M | 52752.00M | 13810.00M | 8346.00M |
| Cash | 23365.00M | 21375.00M | 16921.00M | 10985.00M | 10866.00M |
| Cash and equivalents | 27911.00M | 21375.00M | 16921.00M | 10985.00M | 10866.00M |
| Total current liabilities | 89237.00M | 78292.00M | 72420.00M | 61782.00M | 53209.00M |
| Current deferred revenue | 3075.00M | 2571.00M | 2842.00M | 2622.00M | 2396.00M |
| Net debt | 34258.00M | 24628.00M | 26546.00M | 29693.00M | 25688.00M |
| Short term debt | 3110.00M | 3620.00M | 4819.00M | 3870.00M | 1973.00M |
| Short long term debt | 3110.00M | 3620.00M | 4819.00M | 3870.00M | 1973.00M |
| Short long term debt total | 57623.00M | 46003.00M | 43467.00M | 40678.00M | 36554.00M |
| Other stockholder equity | 3678.00M | 3285.00M | 2837.00M | 2827.00M | 2623.00M |
| Property plant equipment | 10128.00M | 8969.00M | 8626.00M | 8704.00M | 8458.00M |
| Total current assets | 69069.00M | 61758.00M | 53718.00M | 42634.00M | 38692.00M |
| Long term investments | 43728.00M | 43114.00M | 41242.00M | 37209.00M | 32510.00M |
| Net tangible assets | -25084.00000M | 75045.00M | -14491.00000M | -16666.00000M | -14631.00000M |
| Short term investments | 4546.00M | 2532.00M | 2860.00M | 3260.00M | 3458.00M |
| Net receivables | 17681.00M | 14216.00M | 12870.00M | 11822.00M | 11388.00M |
| Long term debt | 54513.00M | 42383.00M | 38648.00M | 36808.00M | 34581.00M |
| Inventory | - | - | - | - | - |
| Accounts payable | 29056.00M | 24483.00M | 21872.00M | 21690.00M | 19891.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 3678.00M | 3285.00M | 2837.00M | 2820.00M | 2623.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8393.00000M | -5384.00000M | -3814.00000M | -3578.00000M | -4160.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 9.00M | 10.00M | 10.00M | 9.00M | 10.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 86156.00M | 77134.00M | 69295.00M | 61178.00M | 55846.00M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 12258.00M | 107334.00M | 102329.00M | 94046.00M | 1852.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 176636.00M | 150448.00M | 143571.00M | 131255.00M | 113529.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 54513.00M | 42383.00M | 38648.00M | 36808.00M | 34581.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -28476.00000M | -1843.00000M | -2836.00000M | -2504.00000M | -4099.00000M |
| Change to liabilities | 6143.00M | -3553.00000M | 5778.00M | 2084.00M | 2395.00M |
| Total cashflows from investing activities | -28476.00000M | -10372.00000M | -12532.00000M | -12699.00000M | -12385.00000M |
| Net borrowings | 12536.00M | 2481.00M | 2586.00M | 3994.00M | 4134.00M |
| Total cash from financing activities | 4226.00M | -7455.00000M | -3590.00000M | -5625.00000M | -4365.00000M |
| Change to operating activities | 2679.00M | 1522.00M | 2895.00M | -342.00000M | 1081.00M |
| Net income | 20639.00M | 17732.00M | 15769.00M | 14239.00M | 12382.00M |
| Change in cash | 1990.00M | 4454.00M | 5936.00M | 119.00M | -1115.00000M |
| Begin period cash flow | 21375.00M | 16921.00M | 10985.00M | 10866.00M | 11981.00M |
| End period cash flow | 23365.00M | 21375.00M | 16921.00M | 10985.00M | 10866.00M |
| Total cash from operating activities | 26206.00M | 22343.00M | 22174.00M | 18463.00M | 15713.00M |
| Issuance of capital stock | 1253.00M | 1355.00M | 1440.00M | 1037.00M | 838.00M |
| Depreciation | 3400.00M | 3103.00M | 2891.00M | 2720.00M | 2428.00M |
| Other cashflows from investing activities | -25674.00000M | -1254.00000M | -7645.00000M | -8124.00000M | -6223.00000M |
| Dividends paid | -5991.00000M | -5280.00000M | -4584.00000M | -3932.00000M | 3320.00M |
| Change to inventory | - | -1031.00000M | -2195.00000M | -1563.00000M | -750.00000M |
| Change to account receivables | -2523.00000M | -1000.00000M | -688.00000M | 162.00M | -1351.00000M |
| Sale purchase of stock | -7000.00000M | -5000.00000M | -4250.00000M | -5500.00000M | -4500.00000M |
| Other cashflows from financing activities | 18979.00M | 4620.00M | 6954.00M | 4520.00M | 5418.00M |
| Change to netincome | -79.00000M | 433.00M | 619.00M | 821.00M | 609.00M |
| Capital expenditures | 2802.00M | 2454.00M | 2051.00M | 2071.00M | 2063.00M |
| Change receivables | -2523.00000M | 1000.00M | -688.00000M | 162.00M | -1351.00000M |
| Cash flows other operating | -1374.00000M | 1031.00M | -2195.00000M | -1563.00000M | -750.00000M |
| Exchange rate changes | - | -62.00000M | -116.00000M | -20.00000M | -78.00000M |
| Cash and cash equivalents changes | 1956.00M | -40232.00000M | 5936.00M | 119.00M | -1115.00000M |
| Change in working capital | 2246.00M | 1522.00M | 2895.00M | 683.00M | 294.00M |
| Stock based compensation | 925.00M | 800.00M | 679.00M | 697.00M | 638.00M |
| Other non cash items | 673.00M | -944.00000M | -52.00000M | 294.00M | 325.00M |
| Free cash flow | 23404.00M | 19889.00M | 20123.00M | 16392.00M | 13650.00M |
Sector: Healthcare Industry: Healthcare Plans
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group Incorporated |
24.41 4.23% | 601.41 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| ELV Elevance Health Inc |
4.65 1.18% | 398.85 | 18.00 | 12.66 | 0.65 | 2.87 | 0.74 | |
| CVS CVS Health Corp |
1.07 1.93% | 56.84 | 12.06 | 9.08 | 0.29 | 1.34 | 0.47 | 8.96 |
| CI Cigna Corp |
0.38 0.12% | 322.88 | 16.80 | 10.45 | 0.46 | 1.90 | 0.58 | |
| HUM Humana Inc |
15.38 5.54% | 293.16 | 19.16 | 14.60 | 0.56 | 3.37 | 0.53 |
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The OptumHealth segment provides care delivery, care management, wellness and consumer engagement, and health financial services for consumers, care delivery systems, providers, employers, payers, and public-sector entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
UnitedHealth Group Center, Minnetonka, MN, United States, 55343
| Name | Title | Year Born |
|---|---|---|
| Sir Andrew Philip Witty | CEO & Director | 1965 |
| Mr. Dirk C. McMahon | Pres & COO | 1960 |
| Mr. John F. Rex | Exec. VP & CFO | 1962 |
| Mr. Brian Robert Thompson | Exec. VP & CEO of UnitedHealthcare | NA |
| Mr. Thomas Edward Roos | Sr. VP & Chief Accounting Officer | 1973 |
| Mr. Sandeep Dadlani | Exec. VP and Chief Digital & Technology Officer | 1975 |
| Mr. Zachary William Sopcak | Sr. VP of Capital Markets Communications & Investor Relations | NA |
| Mr. Rupert Bondy | Exec. VP & Chief Legal Officer | 1962 |
| Ms. Jennifer Mound Smoter | Sr. VP & Chief Communications Officer | NA |
| Mr. James T. Barry Jr. | Director of Sales for Western Pennsylvania | 1946 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...